Cibus
Develops crop traits through gene editing and licenses them to seed companies.
Something off on this page? Send us feedback.
Profile
Develops productivity traits for major row crops using the RTDS and Trait Machine processes. Rather than sell seed, Cibus adapts traits to a customer's elite variety and licenses them for royalties.
Uses RTDS and the Trait Machine process to develop productivity traits for major row crops. Its commercial model edits a cell from a seed company's existing variety, regenerates a plant with the requested trait, and licenses the resulting trait for royalties instead of selling seed.
Development work spans canola, rice, soybean, wheat, and alfalfa, including herbicide-tolerance work in rice and a bio-based fermentation biofragrance program.
Commercial activities sit in one reportable segment and remain a trait-development and licensing pipeline rather than a mature product-revenue portfolio. Commercialization depends on scaling high-quality plants and seed cost-effectively, crop acceptance and performance within seed and downstream systems, regulatory treatment of gene-edited products, commodity-market conditions, and capital availability.
Company facts
Categories
Key statistics
Year to date −11.7% · Average volume (30d) 144.3K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.19 | −$0.29 | −52.6% | $1.7M | $994.0K | −41.7% | −6.84% |
| May 14, 2026Q1 FY26 | −$0.35 | −$0.33 | +5.7% | $1.6M | $1.7M | +4.7% | −7.09% |
| Mar 17, 2026Q4 FY25 | −$0.43 | −$0.42 | +2.3% | $1.6M | $1.1M | −35.7% | −24.73% |
| Nov 13, 2025Q3 FY25 | −$0.41 | −$0.44 | −7.3% | $1.6M | $615.0K | −62.6% | −2.40% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $933.0K | $615.0K | $1.1M | $1.7M | $994.0K | |
| Gross profit | $1.0M | $933.0K | $615.0K | −$4.9M | $484.0K | −$168.0K | |
| Operating income | −$41.6M | −$17.9M | −$15.4M | −$13.5M | −$12.1M | −$12.9M | |
| Net income | −$46.9M | −$25.4M | −$23.5M | −$31.3M | −$21.2M | −$22.1M | |
| Diluted EPS | −$1.34 | −$0.61 | −$0.44 | −$0.39 | −$0.33 | −$0.29 | |
| Gross margin | 100.0% | 100.0% | 100.0% | -460.4% | 28.8% | -16.9% | |
| Operating margin | -4,020.4% | -1,923.5% | -2,510.2% | -1,273.3% | -721.0% | -1,300.3% |
Fiscal years (4-quarter sums)FY21 $26.0M · FY22 $157.0K · FY23 $1.8M · FY24 $4.0M · FY25 $3.6M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $20.4M · Total debt $32.7M · Total assets $313.4M · Shareholders' equity $14.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 76.33M · Float 46.83M · 61.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Rory B. Riggs · director, 10 percent owner: | 14.92M | 19.54% | Form 4 | Feb 2, 2026 |
| FMR LLC | 11.43M | 15.00% | 13G | May 6, 2026 |
| Vanguard Capital Management LLC | 2.12M | 2.78% | 13F | May 15, 2026 |
| Davidson Kempner Capital Management LP | 1.53M | 2.00% | 13F | May 15, 2026 |
| Craig Wichner · officer: CEO | 894.3K | 1.17% | Form 4 | Jun 10, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 13, 2025 | Noel Sauer | officer: Sr VP, Research | −4 | $1.49 |
Peers
- Corteva
Seed traits and gene-edited crop genetics at global scale
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cibus | $1.64 | −1.20% | $125.9M | — | — | 29.0 | +6.5% |
| Corteva | $83.90 | −0.04% | $56.11B | 55.6 | 21.4 | 3.2 | −1.2% |
| Median | 55.6 | 21.4 | 3.2 | −1.2% |